Eagle Genomics Closes $3.5M Investment
Eagle Genomics closes $3.5M investment, led by the Environmental Technologies Fund Investment to enable...read more
UKI2S makes investments for a financial return. It does not provide grants and loans will generally be convertible into equity.
The Fund aims to make a multiple of its investment over a period of 3-8 years, generally by an exit through a trade sale and therefore generally businesses should have high growth potential through serving large markets and establishing barriers to entry. However the Fund does not have a fixed life and is able to make investments between £25,000 and £750,000, so we have made investments in businesses which have modest capital requirements and market size but have a lower risk profile.
The Fund only invests in projects and Small to Medium Enterprises (SME) based in the UK. Companies do not need a business plan, a management team which has sold several businesses before and revenues, but they all help!
The Fund can invest between £25,000 and £750,000 over the lifetime of the business or project
Our advisory board Spectrum has a veto over any investment we make so we usually ask you to come and present to them, but the decision is made by Midven’s investment committee.
This depends very much on how much we are investing and whether investment is needed form other sources. We have made investments in 4 weeks but investments with a large syndicate and where we are investing a few hundred thousand pounds inevitably take significantly longer.
The Fund’s investment can be used for any purpose other than buying out existing shareholders.
No, the Fund’s capital comes from government sources.
The fund actively seeks to syndicate its investments- we are happy to lead funding rounds and share due diligence, or to follow other investors so long as the Fund is making an important contribution. The Fund invests at an early stage to help companies reach significant milestones which make them attractive to later stage investors. Our portfolio companies have raised from other investors 20 times the capital we have invested. We are always keen to engage with later stage investors to understand what companies are of interest and to put forward our companies as well-qualified investment propositions.
Read the full press release here:- https://blog.eaglegenomics.com/microsoft-genomics-ventures-into-the-microbiome-with-eagle-genomicsread more